Cargando…

Survival and neurodevelopmental impairment of outborn preterm infants at 5.5 years of age: an EPIPAGE-2 prospective, matched study using multiple imputation

OBJECTIVE: To determine whether birth outside a level-3 centre (outborn) is associated with a difference in the combined outcome of mortality or moderate-to-severe neurological impairment at 5.5 years of age compared with birth in a level-3 centre (inborn) when antenatal steroids and gestational age...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, Peter, Marchand-Martin, Laetitia, Desplanches, Thomas, Diguisto, Caroline, Fresson, Jeanne, Goffinet, François, Dauger, Stéphane, Ancel, Pierre-Yves, Morgan, Andrei Scott
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9756224/
https://www.ncbi.nlm.nih.gov/pubmed/36645784
http://dx.doi.org/10.1136/bmjpo-2022-001619
_version_ 1784851587383951360
author Jones, Peter
Marchand-Martin, Laetitia
Desplanches, Thomas
Diguisto, Caroline
Fresson, Jeanne
Goffinet, François
Dauger, Stéphane
Ancel, Pierre-Yves
Morgan, Andrei Scott
author_facet Jones, Peter
Marchand-Martin, Laetitia
Desplanches, Thomas
Diguisto, Caroline
Fresson, Jeanne
Goffinet, François
Dauger, Stéphane
Ancel, Pierre-Yves
Morgan, Andrei Scott
author_sort Jones, Peter
collection PubMed
description OBJECTIVE: To determine whether birth outside a level-3 centre (outborn) is associated with a difference in the combined outcome of mortality or moderate-to-severe neurological impairment at 5.5 years of age compared with birth in a level-3 centre (inborn) when antenatal steroids and gestational age (GA) are accounted for. DESIGN: Individual matched study nested within a prospective cohort. Each outborn infant was matched using GA and antenatal steroids with a maximum of four inborns. Conditional logistic regression was used to calculate ORs before being adjusted using maternal and birth characteristics. Analyses were carried out after multiple imputation for missing data. SETTING: EPIPAGE-2 French national prospective cohort including births up to 34 weeks GA inclusive. PATIENTS: Outborn and inborn control infants selected between 24 and 31 weeks GA were followed in the neonatal period and to 2 and 5.5 years. 3335 infants were eligible of whom all 498 outborns and 1235 inborn infants were included—equivalent to 2.5 inborns for each outborn. MAIN OUTCOME MEASURE: Survival without moderate-to-severe neurodevelopmental impairment at 5.5 years. RESULTS: Chorioamnionitis, pre-eclampsia, caesarian birth and small-for-dates were more frequent among inborns, and spontaneous labour and antepartum haemorrhage among outborns. There was no difference in the main outcome measure at 5.5 years of age (adjusted OR 1.09, 95% CI 0.82 to 1.44); sensitivity analyses suggested improved outcomes at lower GAs for inborns. CONCLUSION: In this GA and steroid matched cohort, there was no difference in survival without moderate-to-severe neurodevelopmental impairment to 5.5 years of age between inborn and outborn very preterm children. This suggests steroids might be important in determining outcomes.
format Online
Article
Text
id pubmed-9756224
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-97562242022-12-17 Survival and neurodevelopmental impairment of outborn preterm infants at 5.5 years of age: an EPIPAGE-2 prospective, matched study using multiple imputation Jones, Peter Marchand-Martin, Laetitia Desplanches, Thomas Diguisto, Caroline Fresson, Jeanne Goffinet, François Dauger, Stéphane Ancel, Pierre-Yves Morgan, Andrei Scott BMJ Paediatr Open Neonatology OBJECTIVE: To determine whether birth outside a level-3 centre (outborn) is associated with a difference in the combined outcome of mortality or moderate-to-severe neurological impairment at 5.5 years of age compared with birth in a level-3 centre (inborn) when antenatal steroids and gestational age (GA) are accounted for. DESIGN: Individual matched study nested within a prospective cohort. Each outborn infant was matched using GA and antenatal steroids with a maximum of four inborns. Conditional logistic regression was used to calculate ORs before being adjusted using maternal and birth characteristics. Analyses were carried out after multiple imputation for missing data. SETTING: EPIPAGE-2 French national prospective cohort including births up to 34 weeks GA inclusive. PATIENTS: Outborn and inborn control infants selected between 24 and 31 weeks GA were followed in the neonatal period and to 2 and 5.5 years. 3335 infants were eligible of whom all 498 outborns and 1235 inborn infants were included—equivalent to 2.5 inborns for each outborn. MAIN OUTCOME MEASURE: Survival without moderate-to-severe neurodevelopmental impairment at 5.5 years. RESULTS: Chorioamnionitis, pre-eclampsia, caesarian birth and small-for-dates were more frequent among inborns, and spontaneous labour and antepartum haemorrhage among outborns. There was no difference in the main outcome measure at 5.5 years of age (adjusted OR 1.09, 95% CI 0.82 to 1.44); sensitivity analyses suggested improved outcomes at lower GAs for inborns. CONCLUSION: In this GA and steroid matched cohort, there was no difference in survival without moderate-to-severe neurodevelopmental impairment to 5.5 years of age between inborn and outborn very preterm children. This suggests steroids might be important in determining outcomes. BMJ Publishing Group 2022-12-15 /pmc/articles/PMC9756224/ /pubmed/36645784 http://dx.doi.org/10.1136/bmjpo-2022-001619 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Neonatology
Jones, Peter
Marchand-Martin, Laetitia
Desplanches, Thomas
Diguisto, Caroline
Fresson, Jeanne
Goffinet, François
Dauger, Stéphane
Ancel, Pierre-Yves
Morgan, Andrei Scott
Survival and neurodevelopmental impairment of outborn preterm infants at 5.5 years of age: an EPIPAGE-2 prospective, matched study using multiple imputation
title Survival and neurodevelopmental impairment of outborn preterm infants at 5.5 years of age: an EPIPAGE-2 prospective, matched study using multiple imputation
title_full Survival and neurodevelopmental impairment of outborn preterm infants at 5.5 years of age: an EPIPAGE-2 prospective, matched study using multiple imputation
title_fullStr Survival and neurodevelopmental impairment of outborn preterm infants at 5.5 years of age: an EPIPAGE-2 prospective, matched study using multiple imputation
title_full_unstemmed Survival and neurodevelopmental impairment of outborn preterm infants at 5.5 years of age: an EPIPAGE-2 prospective, matched study using multiple imputation
title_short Survival and neurodevelopmental impairment of outborn preterm infants at 5.5 years of age: an EPIPAGE-2 prospective, matched study using multiple imputation
title_sort survival and neurodevelopmental impairment of outborn preterm infants at 5.5 years of age: an epipage-2 prospective, matched study using multiple imputation
topic Neonatology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9756224/
https://www.ncbi.nlm.nih.gov/pubmed/36645784
http://dx.doi.org/10.1136/bmjpo-2022-001619
work_keys_str_mv AT jonespeter survivalandneurodevelopmentalimpairmentofoutbornpreterminfantsat55yearsofageanepipage2prospectivematchedstudyusingmultipleimputation
AT marchandmartinlaetitia survivalandneurodevelopmentalimpairmentofoutbornpreterminfantsat55yearsofageanepipage2prospectivematchedstudyusingmultipleimputation
AT desplanchesthomas survivalandneurodevelopmentalimpairmentofoutbornpreterminfantsat55yearsofageanepipage2prospectivematchedstudyusingmultipleimputation
AT diguistocaroline survivalandneurodevelopmentalimpairmentofoutbornpreterminfantsat55yearsofageanepipage2prospectivematchedstudyusingmultipleimputation
AT fressonjeanne survivalandneurodevelopmentalimpairmentofoutbornpreterminfantsat55yearsofageanepipage2prospectivematchedstudyusingmultipleimputation
AT goffinetfrancois survivalandneurodevelopmentalimpairmentofoutbornpreterminfantsat55yearsofageanepipage2prospectivematchedstudyusingmultipleimputation
AT daugerstephane survivalandneurodevelopmentalimpairmentofoutbornpreterminfantsat55yearsofageanepipage2prospectivematchedstudyusingmultipleimputation
AT ancelpierreyves survivalandneurodevelopmentalimpairmentofoutbornpreterminfantsat55yearsofageanepipage2prospectivematchedstudyusingmultipleimputation
AT morganandreiscott survivalandneurodevelopmentalimpairmentofoutbornpreterminfantsat55yearsofageanepipage2prospectivematchedstudyusingmultipleimputation